ROG Stock Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.
Roche Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF315.00|
|52 Week High||CHF404.20|
|52 Week Low||CHF298.30|
|1 Month Change||-3.14%|
|3 Month Change||-1.25%|
|1 Year Change||-14.39%|
|3 Year Change||15.30%|
|5 Year Change||30.49%|
|Change since IPO||1,106.90%|
Recent News & Updates
|ROG||CH Pharmaceuticals||CH Market|
Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned -1% over the past year.
Return vs Market: ROG underperformed the Swiss Market which returned -12% over the past year.
|ROG Average Weekly Movement||2.7%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||4.5%|
|10% most volatile stocks in CH Market||8.1%|
|10% least volatile stocks in CH Market||2.4%|
Stable Share Price: ROG is less volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ROG's weekly volatility (3%) has been stable over the past year.
About the Company
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.
Roche Holding Fundamentals Summary
|ROG fundamental statistics|
Is ROG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ROG income statement (TTM)|
|Cost of Revenue||CHF19.82b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Feb 02, 2023
|Earnings per share (EPS)||17.84|
|Net Profit Margin||21.36%|
How did ROG perform over the long term?See historical performance and comparison
3.0%Current Dividend Yield
Is ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ROG?
Other financial metrics that can be useful for relative valuation.
|What is ROG's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ROG's PE Ratio compare to its peers?
|ROG PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
VIFN Vifor Pharma
COPN Cosmo Pharmaceuticals
LLY Eli Lilly
ROG Roche Holding
Price-To-Earnings vs Peers: ROG is good value based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (39.5x).
Price to Earnings Ratio vs Industry
How does ROG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ROG is expensive based on its Price-To-Earnings Ratio (17.7x) compared to the European Pharmaceuticals industry average (17.4x)
Price to Earnings Ratio vs Fair Ratio
What is ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17.7x|
|Fair PE Ratio||43.7x|
Price-To-Earnings vs Fair Ratio: ROG is good value based on its Price-To-Earnings Ratio (17.7x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).
Share Price vs Fair Value
What is the Fair Price of ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ROG (CHF315) is trading below our estimate of fair value (CHF972.07)
Significantly Below Fair Value: ROG is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Roche Holding forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROG's forecast earnings growth (7.5% per year) is above the savings rate (-0.2%).
Earnings vs Market: ROG's earnings (7.5% per year) are forecast to grow slower than the Swiss market (8.8% per year).
High Growth Earnings: ROG's earnings are forecast to grow, but not significantly.
Revenue vs Market: ROG's revenue (3.7% per year) is forecast to grow slower than the Swiss market (4.3% per year).
High Growth Revenue: ROG's revenue (3.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROG's Return on Equity is forecast to be high in 3 years time (37.5%)
Discover growth companies
How has Roche Holding performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROG has high quality earnings.
Growing Profit Margin: ROG's current net profit margins (21.4%) are lower than last year (23.1%).
Past Earnings Growth Analysis
Earnings Trend: ROG's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: ROG's earnings growth over the past year (1%) is below its 5-year average (10.1% per year).
Earnings vs Industry: ROG earnings growth over the past year (1%) underperformed the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: ROG's Return on Equity (53.2%) is considered outstanding.
Discover strong past performing companies
How is Roche Holding's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ROG's short term assets (CHF30.3B) exceed its short term liabilities (CHF27.4B).
Long Term Liabilities: ROG's short term assets (CHF30.3B) do not cover its long term liabilities (CHF30.4B).
Debt to Equity History and Analysis
Debt Level: ROG's net debt to equity ratio (72.3%) is considered high.
Reducing Debt: ROG's debt to equity ratio has increased from 83.5% to 95.9% over the past 5 years.
Debt Coverage: ROG's debt is well covered by operating cash flow (77.9%).
Interest Coverage: ROG's interest payments on its debt are well covered by EBIT (50.5x coverage).
Discover healthy companies
What is Roche Holding current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ROG's dividend (2.95%) is higher than the bottom 25% of dividend payers in the Swiss market (1.8%).
High Dividend: ROG's dividend (2.95%) is low compared to the top 25% of dividend payers in the Swiss market (3.98%).
Stability and Growth of Payments
Stable Dividend: ROG's dividends per share have been stable in the past 10 years.
Growing Dividend: ROG's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (52.1%), ROG's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (43.5%), ROG's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Severin Schwan (55 yo)
Dr. Severin Schwan, Ph D., has been Chief Executive Officer of Roche Holding AG and Roche Holdings, Inc. and Roche Molecular Systems Inc. since March 2008. Dr. Schwan has been Group Chief Executive Officer...
CEO Compensation Analysis
Compensation vs Market: Severin's total compensation ($USD12.19M) is above average for companies of similar size in the Swiss market ($USD7.05M).
Compensation vs Earnings: Severin's compensation has been consistent with company performance over the past year.
Experienced Management: ROG's management team is considered experienced (3 years average tenure).
Experienced Board: ROG's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Roche Holding AG's employee growth, exchange listings and data sources
- Name: Roche Holding AG
- Ticker: ROG
- Exchange: SWX
- Founded: 1896
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF259.904b
- Shares outstanding: 801.09m
- Website: https://www.roche.com
Number of Employees
- Roche Holding AG
- Konzern Hauptsitz
- Grenzacherstrasse 124
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.